Jon mentioned that there was no one in the PW trial who would have to be discontinued off the drug. I.e. they were struggling to recruit patients to the trial so they paused it. They were struggling to recruit because there are other competing phase 2 and 3 trials and you can't be on multiple at once, and if our trial is particularly onerous then why would you go on ours compared to a less onerous option. So given that, then it makes sense to pause the trial, fix up the protocol to make it less onerous, and then consider having another go at recruiting. Plus, then you have a less onerous protocol template you can use for the other pre-clinical indications on the way through.
NEU Price at posting:
$23.11 Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)